Dave Yamauchi

1.2k total citations
35 papers, 713 citations indexed

About

Dave Yamauchi is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dave Yamauchi has authored 35 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Radiology, Nuclear Medicine and Imaging, 15 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dave Yamauchi's work include Radiopharmaceutical Chemistry and Applications (16 papers), Lymphoma Diagnosis and Treatment (11 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Dave Yamauchi is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (16 papers), Lymphoma Diagnosis and Treatment (11 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Dave Yamauchi collaborates with scholars based in United States, Slovakia and France. Dave Yamauchi's co-authors include Andrew Raubitschek, Lawrence E. Williams, Jeffrey Y.C. Wong, Anna M. Wu, John E. Shively, Sharon P. Wilczynski, David Z. J. Chu, Paul J. Yazaki, An Liu and Stephen J. Forman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Dave Yamauchi

33 papers receiving 700 citations

Peers

Dave Yamauchi
Adrian Murray Brunt United Kingdom
Peter Herhaus Germany
Jens Kuhlmann Germany
Michael S. Binkley United States
Gabriele Reinartz Germany
R. P. Baum Germany
Nimisha Deb United States
Lieselot Brepoels Belgium
Roberto Sorasio Italy
R Regnier Belgium
Adrian Murray Brunt United Kingdom
Dave Yamauchi
Citations per year, relative to Dave Yamauchi Dave Yamauchi (= 1×) peers Adrian Murray Brunt

Countries citing papers authored by Dave Yamauchi

Since Specialization
Citations

This map shows the geographic impact of Dave Yamauchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dave Yamauchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dave Yamauchi more than expected).

Fields of papers citing papers by Dave Yamauchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dave Yamauchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dave Yamauchi. The network helps show where Dave Yamauchi may publish in the future.

Co-authorship network of co-authors of Dave Yamauchi

This figure shows the co-authorship network connecting the top 25 collaborators of Dave Yamauchi. A scholar is included among the top collaborators of Dave Yamauchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dave Yamauchi. Dave Yamauchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Poku, Erasmus, et al.. (2025). Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment.. Journal of Clinical Oncology. 43(5_suppl). 123–123. 1 indexed citations
2.
Kuo, Phillip H., Erasmus Poku, Dave Yamauchi, et al.. (2025). Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care. Journal of Nuclear Medicine Technology. 53(4). 300–304.
3.
4.
Hernandez, Matthew C., Paul J. Yazaki, Joanne Mortimer, et al.. (2023). Pilot study of HER2 targeted 64Cu-DOTA-tagged PET imaging in gastric cancer patients. Nuclear Medicine Communications. 44(12). 1151–1155. 4 indexed citations
5.
Wong, Jeffrey Y.C., Firoozeh Sahebi, Savita Dandapani, et al.. (2023). First-in-Human Phase I Trial Combining Biologically Guided Radioimmunotherapy (RIT) Using a 90Y-Anti-CD25 Monoclonal Antibody (Mab) with CT-guided Total Marrow and Lymphoid Irradiation (TMLI) in Relapsed and Refractory (R/R) Acute Leukemia. International Journal of Radiation Oncology*Biology*Physics. 117(2). S162–S162. 1 indexed citations
6.
Akhavan, David, Paul J. Yazaki, Dave Yamauchi, et al.. (2020). Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies. Cancer Biotherapy and Radiopharmaceuticals. 35(1). 10–15. 19 indexed citations
7.
Krishnan, Amrita, Joycelynne Palmer, Auayporn Nademanee, et al.. (2017). Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. Biology of Blood and Marrow Transplantation. 23(6). 922–929. 5 indexed citations
8.
Yamauchi, Dave, et al.. (2014). Exposure Levels Associated With Na131I Thyroid Cancer Patients. Health Physics. 107(2). S163–S165. 2 indexed citations
9.
Yamauchi, Dave, et al.. (2012). Modification of a Motel-Type Room to Accommodate Patients Receiving Radioiodine Therapy. Health Physics. 103(2). S131–S135. 1 indexed citations
10.
Wong, Jeffrey Y.C., Andrew Raubitschek, Dave Yamauchi, et al.. (2010). A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals. 25(4). 387–394. 22 indexed citations
11.
12.
13.
Wong, Jeffrey Y.C., David Z. J. Chu, Lawrence E. Williams, et al.. (2006). A Phase I Trial of 90 Y-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients with Metastatic CEA-Producing Malignancies. Cancer Biotherapy and Radiopharmaceuticals. 21(2). 88–100. 38 indexed citations
14.
Williams, Lawrence E., et al.. (2002). The two types of correction of absorbed dose estimates for internal emitters. Cancer. 94(S4). 1231–1234. 10 indexed citations
15.
Kashyap, Ashwin, Fouad Kandeel, Dave Yamauchi, et al.. (2000). Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study. Biology of Blood and Marrow Transplantation. 6(3). 344–351. 44 indexed citations
16.
Williams, Lawrence E., An Liu, Anna M. Wu, et al.. (2000). Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies. Medical Physics. 27(5). 988–994. 2 indexed citations
17.
Chu, David Z. J., Dave Yamauchi, Lawrence E. Williams, et al.. (2000). A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.. PubMed. 6(10). 3855–63. 63 indexed citations
18.
Wong, Jeffrey Y.C., David Z. J. Chu, Dave Yamauchi, et al.. (1998). Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.. PubMed. 39(12). 2097–104. 17 indexed citations
19.
Colletti, Patrick M., William D. Boswell, D R Radin, et al.. (1990). Computed tomography in endobronchial neoplasms. Computerized Medical Imaging and Graphics. 14(4). 257–262. 25 indexed citations
20.
Beatty, J. David, et al.. (1990). Presurgical imaging with indium-labeled anti-carcinoembryonic antigen for colon cancer staging.. PubMed. 50(3 Suppl). 922s–926s. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adrian Murray Brunt Breakdown of academic impact, for papers by Peter Herhaus Breakdown of academic impact, for papers by Jens Kuhlmann Breakdown of academic impact, for papers by Michael S. Binkley Breakdown of academic impact, for papers by Gabriele Reinartz Breakdown of academic impact, for papers by R. P. Baum Breakdown of academic impact, for papers by Nimisha Deb Breakdown of academic impact, for papers by Lieselot Brepoels Breakdown of academic impact, for papers by Roberto Sorasio Breakdown of academic impact, for papers by R Regnier
Rankless by CCL
2026